Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Proteomics analysis of extracellular vesicles derived from retinal Müller cells under normal and high glucose conditions: implications to diabetic retinopathy
Author Affiliations & Notes
  • Logan Mays
    Medicine, University of Missouri System, Columbia, Missouri, United States
  • Ali Rajooldezfuly
    Medicine, University of Missouri System, Columbia, Missouri, United States
  • Fazle Elahi
    Medicine, University of Missouri System, Columbia, Missouri, United States
  • Thi Nguyen
    Biochemisty, University of Missouri, Columbia, Missouri, United States
  • Brian Mooney
    Biochemisty, University of Missouri, Columbia, Missouri, United States
  • Hu Huang
    Medicine, University of Missouri System, Columbia, Missouri, United States
  • Footnotes
    Commercial Relationships   Logan Mays None; Ali Rajooldezfuly None; Fazle Elahi None; Thi Nguyen None; Brian Mooney None; Hu Huang None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 833. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Logan Mays, Ali Rajooldezfuly, Fazle Elahi, Thi Nguyen, Brian Mooney, Hu Huang; Proteomics analysis of extracellular vesicles derived from retinal Müller cells under normal and high glucose conditions: implications to diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):833.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Müller cells, pivotal glial cells in the retina, have been implicated in the pathogenesis of diabetic retinopathy (DR), yet the mechanisms are unclear. This study focuses on characterizing extracellular vesicles (EVs) or exosomes derived from retinal Müller cells and their proteome under diabetic conditions.

Methods : Human retinal Müller cells (MC: MIO-M1) were cultured under normal glucose (NG: mannitol) and high glucose (HG: 35 mM) for 3 days. EVs were isolated through differential ultracentrifugation and characterized using nanoparticle tracking analysis (NTA) and transmission electron microscopy. Liquid chromatography-tandem mass spectrometry characterized the proteome of cells and EVs. Western blots (WB) and flow cytometry validated differentially expressed proteins (DEPs) between NG and HG conditions, and CD9-GFP reporter mice confirmed EV secretion by MCs.

Results : The EVs’ physical features, particle sizes, concentrations, and morphology are not different between NG/ HG conditions: The mean particle sizes are 143.17 ± 32.25 nm for NG and 148.69 ± 28.26 nm for HG (p=0.18; n = 11). The average concentrations are 1.98E+09 ± 2.12E+09 particles/ml for HG and 2.18E+09 ± 3.43E+09 particles/ml for NG (p=0.17, n=11). The TEM images of HG and NG are similar. Proteomics analysis identified and characterized the proteome of MCs and secreted EVs. Using a protein FDR (false discovery rate) of <1% 7,946 proteins were identified for cells and 2,605 for EVs, with 2,155 in common, 450 only in EVs, and 5,831 only in cells. Compared to NG control, HG upregulates 102 proteins for cells and 92 for EVs and downregulates 218 proteins for cells and 824 for EVs. The EV marker proteins HSP70/90, CD9, CD81, CD63, Syntenin-1, and ESCRT complex I/III were significantly downregulated under HG conditions. Among the DEPs in EVs, ten RNA-binding proteins were selected for validation: ARF3, RBMX, SLP1, UBB, SMARCA2, EIF1AY, 4BPA, SNRPG, AHCYL1, CBX6. The HG-induced downregulation of EVs CD81, CBX6, SMARCA2, and AHCYL1 was validated by WB. Further validation and function studies for EV proteins and in-vivo studies are ongoing.

Conclusions : Diabetes-induced abnormal EV secretion and disrupted protein cargos from Müller cells may contribute to DR development.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×